Technical Support

InertSearch (Application Library)

Index

Application

Document No. Index

LB502 - 596 of Application List

No. Description Column
LB502 Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition) InertSustain Cyano
LB503 Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition, (3) Related subatances) InertSustain Cyano
LB504 Analysis of Fipronil InertSustainSwift C18
LB505 Analysis of Maltooligosaccharides InertSphere Sugar-1
LB506 Analysis of Neonicotinoids InertSustain C18
LB507 Analysis of Fatty acids by LC/MS/MS InertSustain AQ-C18
LB508 Analysis of Sitagliptin (Under the Condition of the draft for the Japanese Pharmacopoeia, Sitagliptin Phosphate Hydrate) InertSustain Cyano
LB509 Analysis of Angiotensin InertSustainBio C18
LB510 Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) InertSustainSwift C18
LB511 Analysis of Parabens, Estradiol and Progesterone InertSustainSwift C18
LB512 Analysis of Pioglitazone hydrochloride (Under the Condition of the draft for USP) InertSustain C18
LB513 Analysis of Peptide hormones InertSustainBio C18
LB514 Analysis of Oligonucleotides InertSustainSwift C18
LB515 Analysis of Caffeine (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Coffee Extract) InertSustain C18
LB516 (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Coffee Extract) InertSustain C18
LB517 Analysis of Glycyrrhizic acid (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Glycyrrhiza Extracted Powder) InertSustain C18
LB518 Analysis of Glycyrrhetinic acid (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Monoammonium α-Glycyrrhizinate) InertSustain C18
LB519 Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) InertSustainSwift C18
LB520 Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) InertSustain C18
LB521 Analysis of Folic acid InertSustain C18
LB522 Analysis of Glutathione and its related compounds InertSustain AQ-C18
LB523 Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) Inertsil C8-3
LB524 Analysis of Telmisartan and Hydrochlorothiazide Inertsil C8-3
LB525 Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) Inertsil C8-3
LB526 Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) Inertsil ODS-4
LB527 Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) Inertsil ODS-4
LB528 Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc) InertSustain C18
LB529 Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc Granules) InertSustain C18
LB530 Analysis of Oligosaccharides derivatized with 2-Aminobenzamide (2-AB) InertSustain Amide
LB531 Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets A) InertSustain C18
LB532 Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets B) InertSustain C18
LB533 Analysis of Dexamathasone Sodium Phosphate (Under the Condition of USP41-NF36, Dexamathasone Sodium Phosphate) Inertsil ODS-3
LB534 Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) InertSustain C8
LB535 Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) InertSustainSwift C8
LB536 Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) InertSustain C18
LB537 Analysis of Suger Alcohol InertSustain Amide
LB538 Analysis of Organic acid SYPRON AX-2
LB539 Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) InertSustain PFP
LB540 Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) InertSustain PFP
LB541 Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) Inertsil C8-4
LB542 Analysis of D-Mannitol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), D-Mannitol and Corn starch compound) InertSphere Sugar-2
LB543 Analysis of Xylooligosaccharides InertSphere Sugar-1
LB544 Analysis of Catecholamines InertSustain AQ-C18
LB545 Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) InertSustainSwift C18
LB546 Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) InertSustainSwift C18
LB547 Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) InertSustain C18
LB548 Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) InertSustain C18
LB549 Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe) InertSustain PFP
LB550 Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) InertSustainSwift C18
LB551 Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) InertSustainSwift C18
LB552 Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine) InertSustain C18
LB553 Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Tablets) InertSustain C18
LB554 Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Orally Disintegrating Tablets) InertSustainSwift C18
LB555 Analysis of Mirtazapine (Under the Condition of draft for USP, Mirtazapine Compounded Oral Suspension, Veterinary) Inertsil ODS-3
LB556 Analysis of Mirtazapine InertSustain C18
LB557 Analysis of 16 Aldehyde (Detected by Pre-Column Method with DNPH) InertSustain PFP
LB558 Analysis of 16 Aldehyde (Detected by Pre-Column Method with DNPH) InertSustain PFP
LB559 Analysis of Artificial sweeteners InertSustain AQ-C18
LB560 Analysis of Advantame (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives)) InertSustain AQ-C18
LB561 Analysis of Neotame (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives)) InertSustain AQ-C18
LB562 Analysis of Steviol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract (4) Steviol) Inertsil ODS-HL
LB563 Analysis of Steviol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract (4) Steviol) InertSustain AQ-C18
LB564 Analysis of Steviol glycosides (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract Assay) Inertsil NH2
LB565 Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Stevia Extract) Inertsil ODS-HL
LB566 Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Stevia Extract) InertSustain AQ-C18
LB567 Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Steviol Glycosides) Inertsil ODS-HL
LB568 Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Steviol Glycosides) InertSustain AQ-C18
LB569 Analysis of Steviol glycosides (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives), Stevia Extract) InertSustain NH2
LB570 Analysis of Steviol glycosides (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives), Stevia Extract) Inertsil NH2
LB571 Analysis of Nicotinamide Adenine Dinucleotide (NADH, NAD+) InertSustain PFP
LB572 Analysis of Nucleosides InertSustain PFP
LB573 Analysis of Dipeptides InertSustain PFP
LB574 Analysis of Catecholamines InertSustain PFP
LB575 Analysis of Tryptophan and its related compounds InertSustain PFP
LB576 Analysis of Uric Acid and its related compounds InertSustain PFP
LB577 Analysis of Glutathione InertSustain PFP
LB578 Analysis of Cysteine and its related compounds InertSustain PFP
LB579 Analysis of Lysine, Methionine, and Carnitine InertSustain PFP
LB580 Analysis of Urea, Ornithine, and Arginine InertSustain PFP
LB581 Analysis of Choline and Acetylcholine InertSustain PFP
LB582 Analysis of Amino Acids InertSustain PFP
LB583 Analysis of Paraquat and Diquat InertSustain PFP
LB584 Analysis of Melamine and its related compounds InertSustain PFP
LB585 Analysis of Unsaturated fatty acids InertSustain PFP
LB586 Analysis of Sterols InertSustain PFP
LB587 Analysis of Eugenol InertSustain PFP
LB588 Analysis of Antidepressants InertSustain PFP
LB589 Analysis of β-blockers InertSustain PFP
LB590 Analysis of Antihistamines InertSustain PFP
LB591 Analysis of Antihistamines InertSustain PFP
LB592 Analysis of Antihistamines InertSustain PFP
LB593 Analysis of Steroids InertSustain PFP
LB594 Analysis of Estrogen InertSustain PFP
LB595 Analysis of Acetyldeoxynivalenol (AcDON) InertSustain PFP
LB596 Analysis of Amino Acids with HILIC mode separtaion InertSustain Amide